[Ethnic differences of genetic polymorphisms in cancer chemotherapy].
The frequency of polymorphisms of CDA was analyzed and the correlation between polymorphisms of CDA and toxicity was evaluated. CDA*3 genotype strongly influenced the metabolism of the drugs and patients with CDA*3 homotype experienced severe toxicity, and the frequency differed among persons of different ethnic origin. Ethnic differences in PK and PD were demonstrated by common arm trials in USA and Japan. Pharmacogenomic differences which determine them should be more intensively been studied.
Saijyo
Nagahiro
N
National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003564:Cytidine Deaminase / Q000235:genetics / Q000378:metabolism; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000208:ethnology / Q000235:genetics* / Q000378:metabolism; D011110:Polymorphism, Genetic / Q000235:genetics*; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D003841:Deoxycytidine; D003564:Cytidine Deaminase; D000093542:Gemcitabine